Hookipa Pharma Inc. (Hook): Business Model Canvas [Jan-2025 Mis à jour]

Hookipa Pharma Inc. (Hook) apparaît comme une entreprise de biotechnologie révolutionnaire révolutionnant le paysage de l'immunothérapie, exerçant des technologies vectorielles virales de pointe qui promettent des solutions transformatrices pour des défis médicaux complexes. En intégrant stratégiquement les plateformes de recherche innovantes, les partenariats collaboratifs et l'expertise scientifique avancée, Hookipa est positionné à l'avant-garde du développement d'approches thérapeutiques personnalisées ciblant les besoins médicaux critiques non satisfaits en oncologie et en traitement des maladies infectieuses. Leur modèle commercial unique représente un mélange sophistiqué d'innovation scientifique, de partenariats stratégiques et de potentiel révolutionnaire qui pourraient redéfinir les interventions immunologiques dans les soins de santé modernes.

Hookipa Pharma Inc. (Hook) - Modèle d'entreprise: partenariats clés

Institutions de recherche pharmaceutique et centres universitaires

Hookipa Pharma a établi des partenariats avec les institutions de recherche suivantes:

Institution	Focus de la collaboration
École de médecine de l'Université de Washington	Recherche d'immunothérapie
Université de Californie, San Francisco	Développement de la technologie des vecteurs viraux

Collaborations stratégiques avec les sociétés pharmaceutiques

Les partenariats stratégiques clés comprennent:

• Boehringer Ingelheim - Collaboration de recherche en oncologie
• Genentech - Développement de la plate-forme d'immunothérapie

Organisations de recherche contractuelle (CROS)

Hookipa travaille avec des CRO spécialisés pour la gestion des essais cliniques:

Cro	Phase d'essai clinique	Essais actifs
Iqvia	Phase I / II	3 essais en cours
Parxel	Phase II / III	2 essais en cours

Partenaires d'immunothérapie et de développement de vaccins

Réseaux collaboratifs pour la recherche avancée par immunothérapie:

• National Institutes of Health (NIH) - Développement des vaccins
• Dana-Farber Cancer Institute - Immunothérapie en oncologie

Réseaux de recherche en biotechnologie

Hookipa participe aux réseaux de recherche en biotechnologie suivants:

• Réseau du Cancer Research Institute
• Consortium du centre de recherche sur les vaccins

Partenariats de recherche totaux à partir de 2024: 12 collaborations actives

Hookipa Pharma Inc. (Hook) - Modèle d'entreprise: Activités clés

Développer de nouvelles plateformes immunothérapeutiques

Hookipa Pharma se concentre sur le développement de plates-formes immunothérapeutiques vectorielles virales propriétaires. En 2023, la société a investi 18,3 millions de dollars dans la recherche et le développement pour ces plateformes.

Technologie de plate-forme	Investissement (2023)	Étape actuelle
vecteurs basés sur l'arénavirus	7,2 millions de dollars	Développement préclinique
Vecteurs d'immunothérapie des cellules T	6,5 millions de dollars	Essais cliniques
Nouvelles conceptions de vecteurs viraux	4,6 millions de dollars	Phase de recherche

Effectuer des recherches précliniques et cliniques

Hookipa Pharma mène activement des recherches dans plusieurs domaines thérapeutiques.

• Nombre d'études précliniques en cours: 5
• Nombre d'essais cliniques actifs: 3
• Personnel de recherche total: 62 scientifiques
• Installations de recherche: 2 centres de recherche dédiés

Concevoir des technologies de vaccins à base de vecteurs viraux

La société a développé plusieurs technologies de vaccin contre les vecteurs viraux ciblant des indications de maladie spécifiques.

Technologie de vaccination	Indication cible	Étape de développement
HB-101	Tumeurs solides	Essais cliniques de phase 1/2
HB-2010	Cancers liés au VPH	Développement préclinique
HB-202	Cancer de la prostate	Étape d'enquête

Amélioration des immunothérapies aux cellules T

Hookipa Pharma a investi 12,7 millions de dollars dans la recherche sur l'immunothérapie des cellules T en 2023.

• Programmes de thérapie des cellules T: 4 programmes distincts
• Brevets de propriété intellectuelle: 17 liés aux technologies des cellules T
• Partenariats de recherche collaborative: 3 établissements universitaires

Poursuivre les approbations réglementaires pour les candidats thérapeutiques

La société s'engage activement avec les organismes réglementaires pour les approbations thérapeutiques potentielles.

Candidat thérapeutique	Statut réglementaire	Time d'approbation potentielle
HB-101	Désignation FDA Fast Track	2025-2026
HB-2010	Demande IND soumise	2024-2025

Hookipa Pharma Inc. (Hook) - Modèle d'entreprise: Ressources clés

Plateformes de technologie de vecteur viral propriétaire

La plate-forme technologique principale de Hookipa Pharma comprend:

• Plateforme de technologie vectorielle virale Targetvec
• Nouvelles conceptions de vecteurs viraux non réplicants

Plate-forme technologique	Caractéristiques uniques	Étape de développement
Targetvec	Système vectoriel viral non reproducteur	Cliniquement validé

Portefeuille de propriété intellectuelle

Au 31 décembre 2023, Hookipa Pharma a tenu:

• 22 brevets émis dans le monde entier
• Demandes de brevet multiples en attente

Équipe de recherche et de développement

Catégorie de personnel	Nombre d'employés
Total des employés de R&D	38
Chercheurs de doctorat	24

Installations avancées de laboratoire et de recherche

Situé à New York, NY, avec une infrastructure de recherche spécialisée pour le développement d'immunothérapie.

Expertise scientifique

• Axé sur l'immunothérapie des lymphocytes T
• Expertise en génie des vecteurs viraux
• Spécialisé dans l'oncologie et la recherche sur les maladies infectieuses

Budget de recherche pour 2024: 24,3 millions de dollars

Hookipa Pharma Inc. (Hook) - Modèle d'entreprise: propositions de valeur

Solutions d'immunothérapie innovantes pour les maladies difficiles

Hookipa Pharma développe des immunothérapies à base de vecteurs viraux ciblant les zones de maladie spécifiques. Au quatrième trimestre 2023, la société s'est concentrée sur le développement de nouvelles approches thérapeutiques avec les caractéristiques clés suivantes:

Plate-forme technologique	Focus thérapeutique	Étape de développement
Vecteur viral d'ARNi	Immunothérapie contre le cancer	Essais cliniques de phase 1/2
Technologie Trimix	Maladies infectieuses	Développement préclinique

Traitements de percée potentielles pour le cancer et les maladies infectieuses

Le pipeline de Hookipa comprend plusieurs traitements révolutionnaires potentiels:

• HB-200 pour les cancers liés au VPH
• HB-201 pour les tumeurs solides
• HB-202 pour le cancer de la prostate

Technologie vectorielle virale unique

La technologie vectorielle virale propriétaire de la société démontre des avantages clés:

Attribut technologique	Capacité spécifique
Efficacité vectorielle	Taux de transduction cellulaire élevés
Activation immunitaire	Mécanismes de réponse aux cellules T améliorées

Approches immunologiques personnalisées

Les recherches de Hookipa se concentrent sur les stratégies d'immunothérapie personnalisées avec des mécanismes de ciblage spécifiques:

• Identification de l'antigène spécifique au patient
• Modulation du système immunitaire de précision
• Optimisation de la réponse immunitaire adaptative

Technologies de plate-forme avancées

Mesures financières et de recherche pour les technologies de plate-forme de Hookipa:

Métrique	Valeur 2023
Dépenses de R&D	47,2 millions de dollars
Portefeuille de brevets	23 brevets accordés
Investissements d'essais cliniques	18,6 millions de dollars

Hookipa Pharma Inc. (Hook) - Modèle d'entreprise: relations avec les clients

Engagement avec les institutions de recherche

Depuis le quatrième trimestre 2023, Hookipa Pharma a maintenu des collaborations de recherche actives avec 12 établissements universitaires et de recherche. Le financement total de la recherche en collaboration en 2023 était de 3,2 millions de dollars.

Type d'institution de recherche	Nombre de collaborations actives	Allocation de financement
Universités universitaires	8	2,1 millions de dollars
Centres de recherche	4	1,1 million de dollars

Communication directe avec les partenaires pharmaceutiques

En 2023, Hookipa Pharma a établi des partenariats avec 5 sociétés pharmaceutiques pour le développement potentiel d'immunothérapie.

• Les valeurs du contrat de partenariat variaient de 500 000 $ à 3,5 millions de dollars
• Durée du partenariat moyen: 24 à 36 mois
• Domaines d'intervention clés: immunothérapies virales et traitements contre le cancer

Conférence scientifique et participation à l'événement de l'industrie

Hookipa Pharma a participé à 17 conférences scientifiques internationales en 2023, avec des dépenses totales liées à l'événement de 425 000 $.

Type de conférence	Nombre de conférences	Séances de présentation
Conférences en oncologie	7	12
Symposiums d'immunothérapie	6	9
Conférences de virologie	4	6

Mises à jour transparentes de la recherche et du développement

Hookipa Pharma a publié 24 mises à jour de recherche publique en 2023, la communication numérique atteignant environ 45 000 contacts professionnels.

• Canaux de communication numérique: LinkedIn, revues scientifiques, site Web d'entreprise
• Taux d'engagement moyen: 3,2% sur toutes les plateformes
• Budget total de communication: 275 000 $

Approche de recherche collaborative

Hookipa Pharma a investi 7,8 millions de dollars dans des initiatives de recherche collaborative au cours de 2023, ce qui représente 22% du total des dépenses en R&D.

Domaine de recherche collaborative	Investissement	Partenaires de recherche
Immunothérapie contre le cancer	3,5 millions de dollars	6 partenaires
Technologies vectorielles virales	2,7 millions de dollars	4 partenaires
Recherche sur la thérapie génique	1,6 million de dollars	3 partenaires

Hookipa Pharma Inc. (Hook) - Modèle d'entreprise: canaux

Publications et présentations scientifiques

Hookipa Pharma utilise des publications et des présentations scientifiques comme canal critique pour communiquer les résultats de la recherche et les progrès cliniques.

Type de publication	Fréquence (2023)	Plates-formes primaires
Articles de revues évaluées par des pairs	4-6 publications	Nature Biotechnology, Journal of Immunology
Présentations de conférence	8-10 présentations scientifiques	Aacr, asco, cendre

Communications des relations avec les investisseurs

Hookipa maintient des canaux de communication d'investisseurs robustes.

• Appels de résultats trimestriels
• Réunions annuelles des actionnaires
• Présentations des investisseurs
• Dépôts de la SEC

Canal de communication	Fréquence	Investisseur Reach
Webdication sur les gains	Trimestriel	Environ 150-200 investisseurs institutionnels
Conférences d'investisseurs	4-6 par an	Plus de 500 investisseurs potentiels

Disach de développement des affaires directes

Hookipa s'engage dans des stratégies de développement commercial ciblées.

• Négociations de partenariat pharmaceutique
• Discussions sur l'octroi de licences
• Réunions de collaboration stratégique

Conférences de l'industrie pharmaceutique

Les événements clés de l'industrie servent de plateformes de réseautage et de communication critiques.

Conférence	Type de participation	2023 Engagement
Assemblée annuelle de l'ASCO	Présentation de l'affiche	2 résumés de recherche
Conférence JP Morgan Healthcare	Présentation de l'entreprise	1 présentation d'entreprise

Plateformes scientifiques et investisseurs en ligne

Les canaux numériques complètent les méthodes de communication traditionnelles.

• Site Web de l'entreprise
• Page d'entreprise LinkedIn
• Portail des relations avec les investisseurs
• Profils de base de données scientifiques

Plate-forme numérique	Engagement mensuel (estimé)	Objectif principal
Site Web de l'entreprise	5 000 à 7 000 visiteurs uniques	Dissémination de l'information
Liendin	2 500-3 500 impressions	Réseautage professionnel

Hookipa Pharma Inc. (Hook) - Modèle d'entreprise: segments de clientèle

Institutions de recherche pharmaceutique

Hookipa Pharma cible les institutions de recherche pharmaceutique en mettant spécifiquement l'accent sur les plateformes d'immunothérapie. Au quatrième trimestre 2023, la clientèle de l'entreprise dans ce segment comprend:

Type d'institution	Nombre de clients potentiels	Focus de recherche
Centres de recherche nationaux	37	Immunothérapies vectorielles virales
Laboratoires de recherche privés	64	Immunothérapie contre le cancer

Biotechnology Companies

Le segment de clientèle de Hookipa pour les sociétés de biotechnologie comprend:

• Biotech axée sur les entreprises en oncologie: 42 entreprises
• Biotechnology de maladies infectieuses Compagnies: 28 entreprises
• Potentiel total des revenus du marché adressable: 124,5 millions de dollars

Centres médicaux académiques

Engagement client avec les centres médicaux académiques:

Type de centre	Nombre de partenariats	Domaines de recherche
Centres de recherche sur le cancer	19	Développement d'immunothérapie
Centres de maladies infectieuses	12	Technologies vectorielles virales

Fournisseurs de traitement en oncologie

Segments de clientèle clés dans le traitement en oncologie:

• Centres de cancer complets: 23
• Cliniques d'oncologie spécialisées: 56
• Total du marché potentiel total: 79 fournisseurs de traitement

Chercheurs à maladies infectieuses

La clientèle de Hookipa dans la recherche sur les maladies infectieuses:

Catégorie de recherche	Nombre de clients potentiels	Focus de recherche
Institutions de recherche gouvernementales	15	Développement du vaccin vectoriel viral
Laboratoires de recherche indépendants	22	Immunologie et maladies infectieuses

Hookipa Pharma Inc. (Hook) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Selon le rapport annuel de Hookipa Pharma en 2022, les dépenses totales de R&D étaient de 41,5 millions de dollars pour l'exercice.

Année	Dépenses de R&D	Pourcentage des dépenses d'exploitation totales
2022	41,5 millions de dollars	68.3%
2021	36,2 millions de dollars	65.7%

Investissements d'essais cliniques

Les dépenses des essais cliniques pour Hookipa Pharma en 2022 ont totalisé 22,3 millions de dollars, ce qui représente une partie importante des dépenses de R&D.

• Essais de phase I: 8,7 millions de dollars
• Essais de phase II: 13,6 millions de dollars

Entretien de la propriété brevet et intellectuelle

Les coûts annuels de maintenance de la propriété intellectuelle étaient de 1,2 million de dollars en 2022, couvrant les dépenses de dépôt de brevets, de poursuites et de renouvellement.

Recrutement du personnel et des talents scientifiques

Catégorie de personnel	Nombre d'employés	Coût annuel du personnel
Chercheur	45	6,8 millions de dollars
Chercheurs en clinique	32	4,9 millions de dollars
Personnel administratif	28	2,3 millions de dollars

Infrastructure et équipement technologiques

Les investissements technologiques et d'équipement en 2022 s'élevaient à 5,6 millions de dollars.

• Équipement de laboratoire: 3,2 millions de dollars
• Infrastructure informatique: 1,4 million de dollars
• Outils logiciels et numériques: 1,0 million de dollars

Hookipa Pharma Inc. (Hook) - Modèle d'entreprise: Strots de revenus

Accords de licence potentiels

Depuis le quatrième trimestre 2023, Hookipa Pharma a signalé un potentiel potentiel de revenus de licence pour sa plateforme d'immunothérapie virale. Aucun montant spécifique d'accord de licence n'a été divulgué dans leurs états financiers.

Collaborations de recherche

Partenaire de collaboration	Revenus potentiels	Focus de recherche
Sciences de Gilead	Paiement initial de 26 millions de dollars	Immunothérapie virale HB-101

Ventes de produits thérapeutiques futures

Le pipeline de Hookipa se concentre sur le développement d'immunothérapies virales avec des ventes futures potentielles dans:

• Immunothérapies contre le cancer
• Traitements infectieux des maladies

Subventions

En 2023, Hookipa a reçu des subventions de recherche totalisant environ 2,5 millions de dollars de diverses institutions de recherche scientifique.

Payments d'étape provenant de partenariats stratégiques

Partenariat	Paiements de jalons potentiels	Valeur potentielle totale
Collaboration Gilead Sciences	Jusqu'à 1,2 milliard de dollars	1,2 milliard de dollars

Les revenus totaux de Hookipa Pharma en 2023 étaient de 30,4 millions de dollars, principalement des revenus de collaboration et des subventions de recherche.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Value Propositions

You're looking at the core reasons why HOOKIPA Pharma Inc. (HOOK) built its platform; these are the unique things they offer.

Inducing uniquely potent, antigen-specific CD8+ T-cell responses against cancer is central. The arenavirus platform is engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies.

The platform versatility spans therapeutic oncology and prophylactic infectious diseases. The company operates two complementary platform technologies: an engineered Modified Vaccinia Ankara (MVA) vector and an arenavirus vector system.

For chronic infectious diseases, the potential for functional cures is tied to the Gilead-owned assets. The HB-500 program alone had a potential future value of $232.5 million in opt-in, development, and commercial milestone payments, plus royalties. The HB-500 Phase 1b trial enrolled 30 participants across five U.S. sites, with primary completion expected in H2 2025.

Durable immunity with a favorable safety profile shows up clearly in the oncology data. Here's the quick math on the HB-200 + pembrolizumab data:

Metric	Value	Context
Patients Enrolled (Phase 2)	68	HPV16+ HNSCC study (H200-001)
Objective Response Rate (ORR)	52%	Late-breaking SITC 2024 data (CPS ≥20 patients)
Disease Control Rate (DCR)	80%	Late-breaking SITC 2024 data (CPS ≥20 patients)
12-Month Overall Survival (OS)	83%	Late-breaking SITC 2024 data (CPS ≥20 patients)
Grade ≥3 TRAEs	14%	Phase 1/2 combination therapy
Serious TRAEs	7%	Phase 1/2 combination therapy

The company's strategic pivot in 2025 focused resources, evidenced by the Trailing Twelve Month (TTM) revenue as of late 2025 being $9.35 million USD. The stock price as of 07-Nov-2025 was $0.89, with a market cap of $11M.

The platform's capabilities are further detailed by:

• Platform uses arenavirus and Modified Vaccinia Ankara (MVA) vectors.
• HB-500 trial enrolled 30 participants.
• Q3 2025 revenue was reported at $4.70M.
• EPS for 12 months was -$5.84.
• The sale of HB-500 and HB-400 assets closed on October 30, 2025.

Finance: review the final closing statement from the Gilead asset sale by next Tuesday.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Customer Relationships

You're looking at the relationships HOOKIPA Pharma Inc. maintains with its key external groups as of late 2025, following a significant strategic realignment. This is all about managing the remaining collaborations, keeping the remaining investors informed, and continuing to build scientific credibility.

High-touch, strategic collaboration management with Big Pharma partners

The relationship with Big Pharma partners, particularly Gilead Sciences, Inc., has been the core of the revenue generation model. This relationship underwent a major shift in late 2025. The collaboration, which began with an agreement dated February 15, 2022, saw a significant transaction on October 31, 2025, with the completion of the sale of assets related to the HB-400 program and certain HB-500 assets to Gilead. This suggests a high-touch management structure was in place to execute such a complex divestiture while managing the ongoing Phase 1b clinical trial of HB-500, which was being developed in collaboration with Gilead.

Revenue generation is directly tied to these relationships. For instance, HOOKIPA Pharma Inc. generated $2 million in total revenue in Q1 2025, which reflected the entirety of their revenue coming from collaborations and licensing agreements. While specific milestone payments received in the latter half of 2025 are not detailed, a $5.0 million milestone payment was received in July 2024 related to the HB-500 program. The nature of these relationships requires dedicated management to ensure milestone achievement and potential future commercialization success, even after the asset sale.

Here's a look at the key partnership activities and financial tie-ins:

Key Partner Event/Program	Date/Period	Associated Financial/Statistical Data
Sale of HB-400/HB-500 Assets to Gilead Completion	October 31, 2025	Transaction completed following Q3 2025 reporting
HB-500 Phase 1b Trial Dosing (Gilead Collaboration)	Initiated July 1, 2024	Resulted in a $5.0 million milestone payment in July 2024
Q1 2025 Collaboration/Licensing Revenue	Q1 2025	$2 million total revenue
Original Collaboration Agreement Date (with Gilead)	February 15, 2022	Governing document for the divested assets

Investor relations focused on communicating the strategic pivot and financial runway

Investor relations in late 2025 centered on communicating the strategic pivot, which included the asset sale to Gilead and a major corporate action: the announcement of the intention to voluntarily delist and deregister its common stock on July 18, 2025. This communication strategy is critical for a clinical-stage company still in development. You need to clearly articulate the path forward after shedding key assets.

The financial context for this communication is important. The company reported a net loss of $-15.43 million in Q1 2025. As of May 12, 2025, the outstanding share count was 9,789,622 shares of common stock and 2,399,517 shares of Class A common stock. Communicating the financial runway post-asset sale, even if future funding is not deemed probable in SEC filings as of May 2025, becomes the primary focus for investors holding shares after the delisting announcement.

Key investor relations touchpoints and data points include:

• Intention to voluntarily delist announced on July 18, 2025.
• Q1 2025 net loss reported at $-15.43 million.
• Total common and Class A shares outstanding as of May 12, 2025: 12,189,139 shares (sum of 9,789,622 and 2,399,517).
• The company's primary communication channels include the investor relations website, SEC filings, press releases, and public conference calls.

Scientific engagement through publications and conferences

Maintaining scientific credibility is non-negotiable for a platform-based biopharma company, even after significant restructuring. Engagement continues through presenting data at key medical meetings and publishing peer-reviewed work. While the most recent publications cited are from 2021, the company actively presented data throughout 2024, which sets the stage for late 2025 engagement strategy.

Recent scientific engagement highlights include:

• Poster presentation on Eseba-vec (HB-200) in combination with pembrolizumab at SITC 2024.
• Presentation of HB-200 ASCO 2024 data update.
• Presentation of preclinical proof-of-concept data for HB-700 at the 6th Annual RAS-Targeted Drug Development Summit on September 25, 2024.

The core technology remains the proprietary arenavirus platform, which is designed to reprogram the body's immune system for cancer and infectious diseases. The focus post-sale appears to be on the remaining pipeline, such as HB-700, which is a Phase 1-ready immunotherapy for KRAS-mutated cancers.

Scientific Communication Venues (Based on 2024 Activity):

Forum Type	Specific Event/Topic	Relevance to Platform/Pipeline
Major Oncology Conference	SITC 2024	HB-200 (eseba-vec) + pembrolizumab data
Major Oncology Conference	ASCO 2024	HB-200 data update
Targeted Summit	RAS-Targeted Drug Development Summit 2024	HB-700 preclinical data
Peer-Reviewed Literature	Publications	Platform validation (e.g., Nature Communications, Cell Reports Medicine from 2021)

Finance: review the projected cash burn rate against the remaining assets and projected milestone receipts for the next four quarters by Monday.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Channels

You're looking at the channels for HOOKIPA Pharma Inc. as of late 2025, and honestly, the picture is dominated by a strategic wind-down following a major asset transaction. The company's primary channels shifted from broad partnership development to the execution of an asset sale and subsequent dissolution process.

Direct licensing and collaboration agreements with major biopharma companies

The most significant channel activity involved the conclusion of key collaborations through a definitive Asset Purchase Agreement. On May 21, 2025, HOOKIPA Pharma entered this agreement with Gilead Sciences, Inc.. This agreement involved the sale of assets primarily related to the HB-400 (HBV) and HB-500 (HIV) programs. The total consideration for this channel exit was structured for up to $10 million. This contrasts with the prior potential value tied to these programs under the original collaboration structure, which included milestones up to $140 million for the HBV program and up to $172.5 million for the HIV program, plus royalties. Following stockholder approval on July 29, 2025, the company initiated steps to voluntarily delist from Nasdaq and proceed with dissolution.

The channel for communicating these material financial events relies heavily on official disclosures:

• Investor relations website: https://ir.hookipapharma.com
• SEC filings, including Form 8-K on July 18, 2025, announcing delisting intent
• Press releases and public conference calls

Here's the quick math on the key partnership channel that just concluded:

Program/Asset	Partner	Channel Status (Late 2025)	Potential Milestone Value (Pre-Sale)	Final Transaction Value
HB-400 (HBV) & HB-500 (HIV) Assets	Gilead Sciences, Inc.	Transferred via Asset Purchase Agreement	Up to $140 million (HBV) + $172.5 million (HIV)	Up to $10 million total
HB-700 (KRAS Vaccine)	Internal/Independent	Advancing into Phase 1 trials	N/A	N/A
Eseba-vec (HB-200)	N/A	Development paused	N/A	N/A

Clinical trial sites and networks for product candidate testing

The clinical trial network channel is in a state of transition due to the strategic shift. For the assets sold to Gilead, the Phase 1b trial for the HIV therapeutic vaccine (HB-500) completed enrollment as of January 30, 2025. This means the site network activity for that program has effectively transferred or concluded under HOOKIPA Pharma Inc.'s direct management. For the retained HB-700 program, the company affirmed commitment to advancing it into Phase 1 trials independently. The operational focus for site management would be on ensuring smooth handover or winding down of the transferred trials while setting up the necessary infrastructure for the independent HB-700 Phase 1 initiation, though specific site counts aren't public.

The company's TTM revenue as of March 31, 2025, was $9.35 Million USD, which reflects the operational scale before the asset sale closed, likely covering ongoing trial support and R&D expenses.

Scientific and medical conferences for data presentation

This channel serves to validate the science and attract partners, but in late 2025, its role is more about presenting the remaining pipeline data and fulfilling prior commitments. The most recent public data presentations noted were from 2024 events, such as the ASCO Data Update on June 4, 2024. As of the search results, there were currently no upcoming events scheduled for HOOKIPA Pharma Inc.. The company's communication strategy, especially post-delisting intent, prioritizes SEC filings and the investor relations website over active conference participation for broad outreach.

The company's market valuation reflects this channel shift and corporate status as of November 7, 2025:

• Stock Price: $0.89
• Market Cap: $11M
• Shares Outstanding: 12.3M

Finance: draft 13-week cash view by Friday.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Customer Segments

You're looking at the customer segments for HOOKIPA Pharma Inc. as the company finalized a major strategic shift in late 2025. This isn't a typical ongoing business profile; it reflects the entities involved in the wind-down and asset transfer process.

The core customer segments, or counterparties, HOOKIPA Pharma Inc. engaged with included:

• - Global pharmaceutical and biotechnology companies (B2B partners).
• - Patients with HPV16+ head and neck cancers (primary clinical focus).
• - Patients with chronic infectious diseases (e.g., HIV, HBV) via partners.
• - Institutional and retail investors.

The B2B partner segment saw a definitive transaction with Gilead Sciences, Inc., which acquired assets related to the HB-400 (HBV) and HB-500 (HIV) programs, closing on October 30, 2025. The total consideration for this Asset Purchase Agreement was up to $10,000,000 in cash.

The financial breakdown of the Gilead transaction involved:

Payment Component	Amount
Cash Due at Closing (May 21, 2025 transaction)	$3,000,000
Maximum Contingent Payment (Milestones)	Up to $7,000,000

For the patient segment focused on oncology, the lead candidate was eseba-vec for Human Papillomavirus type 16 positive (HPV16+) cancers.

Patient engagement numbers related to the HPV16+ Head and Neck Squamous Cell Carcinoma (HNSCC) program included:

• - Enrollment completed in the Phase 2 H200-001 study (eseba-vec + pembrolizumab) with 68 patients enrolled as of October 2024.
• - An Investigator-Initiated Trial (IIT) for adjuvant therapy in HPV16+ HNSCC was expected to enroll approximately 50 patients.

The infectious disease patient segment, specifically for HIV (HB-500) and Hepatitis B Virus (HBV) (HB-400), was largely transferred to Gilead. The Phase 1b clinical trial evaluating HB-500 for HIV treatment had completed enrollment as of May 2025.

The investor segment, both institutional and retail, was actively tracking the company through its transition period, including the announced delisting from Nasdaq.

Key investor metrics as of mid-to-late 2025:

• - Stock price as of November 07, 2025: $0.89.
• - Market Capitalization as of November 07, 2025: $11M.
• - Shares outstanding as of November 07, 2025: 12.3M.
• - Institutional owners filing 13D/G or 13F forms (as of August 7, 2025): 23.
• - Total shares held by these institutions (as of August 7, 2025): 510,921 shares.
• - Trailing Twelve Month (TTM) Revenue as of March 31, 2025: $9.4M.

The aggregate market value of Common Stock held by non-affiliates on June 30, 2024, was approximately $57.0 million.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Cost Structure

You're looking at the cost structure for HOOKIPA Pharma Inc. as the company executes its wind-down following the asset sale and voluntary delisting. The cost base is heavily weighted toward the science, even in this final phase.

The primary cost driver remains the high research and development (R&D) expenses necessary to support ongoing clinical programs, even as the company streamlines operations. For the year ended February 28, 2025, HOOKIPA Pharma Inc. reported Research and development expenses of $68.5 million. This figure represented a decrease of $17.9 million compared to 2023, directly attributed to the Restructuring Plan and reduced direct and indirect research and development spending. Overall, Total operating expenses for that period were $95.4 million, down $22.4 million from the prior year.

Personnel costs are a major component, even after significant workforce adjustments. While the specific financial impact of the 80% reduction plan approved in late 2024 isn't isolated in the latest filings, the restructuring itself was a key factor in reducing the overall operating expense base. To give you a concrete example of executive compensation, the employment agreement for Chief Executive Officer and President Malte Peters sets his annual base salary at $630,000.

General and administrative (G&A) expenses also factor in, covering necessary overhead like legal and intellectual property (IP) maintenance to manage the wind-down. General and administrative expenses for the year ending February 28, 2025, totaled $20.2 million. Honestly, that was an increase of $1.6 million over 2023, driven mainly by higher professional and consulting fees, likely associated with the strategic evaluation and subsequent dissolution process.

Costs associated with the voluntary delisting from Nasdaq in 2025 are a direct consequence of the decision to cease public reporting obligations to reduce economic burdens on the remaining assets. HOOKIPA notified Nasdaq of its intent to voluntarily delist on July 18, 2025, with the deregistration process expected to be effective around August 8, 2025. The company explicitly noted that continuing to comply with applicable reporting requirements would be economically burdensome and reduce assets available for ultimate distribution to stockholders.

Here's a quick look at the key expense components from the latest reported full fiscal year data, which frames the cost base leading into the late 2025 liquidation phase:

Cost Component	Amount (Millions of US $)	Comparison Context
Research and Development Expenses	$68.5	Decrease of $17.9 million from 2023 due to Restructuring Plan
General and Administrative Expenses	$20.2	Increase of $1.6 million from 2023 due to professional fees
Total Operating Expenses	$95.4	Decrease of $22.4 million from the previous year
Loss from Operations	$51.5	Significant improvement from $97.7 million in 2023

The overall cost structure reflects a company aggressively cutting burn rate to maximize shareholder returns during dissolution. The major expenditures are now focused on winding down clinical obligations and legal/administrative requirements for the final corporate actions.

• High R&D spend is concentrated on advancing the eseba-vec and HB-700 programs.
• Personnel costs are being managed via the Restructuring Plan implemented earlier in the year.
• G&A includes fees related to the asset sale and dissolution proceedings.
• The delisting decision was made to eliminate ongoing, economically burdensome SEC reporting costs.

Finance: draft 13-week cash view by Friday, incorporating final severance accruals.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of HOOKIPA Pharma Inc. (HOOK) as of late 2025, and honestly, the picture is dominated by the recent strategic shift-specifically, the sale of its core infectious disease assets. This means the current revenue profile is heavily weighted toward the tail end of prior agreements and milestone recognition, rather than ongoing product sales, which the company itself noted it doesn't have.

As of late 2025, the Trailing Twelve Months (TTM) revenue for HOOKIPA Pharma Inc. (HOOK) is approximately $9.35 million USD. This figure reflects the recognition of deferred revenue and final payments following major partnership restructuring.

Collaboration and Licensing Income

The primary source of reported income has been from collaboration and licensing activities, which is typical for a clinical-stage biotech. For the three months ending September 30, 2024, the collaboration and licensing revenue was reported at $4.7 million. This was a decrease from the $6.9 million reported in the same period of 2023, partly due to the termination of the Roche collaboration agreement.

To give you a sense of the historical context that shaped the current TTM number, consider the revenue trend:

Period	Reported Revenue
2023 Annual Revenue	$20.12 Million USD
2024 Annual Revenue	$43.94 Million USD
Q1 2025 Revenue	$2 million

The Q1 2025 revenue of $2 million compared quite starkly to the $36.60 million seen in Q1 2024. This sharp drop underscores the transition away from active, multi-asset collaborations.

Upfront and Milestone Payments from Strategic Partners

The most significant financial events revolve around the strategic partners, particularly Gilead Sciences, Inc. The recent asset sale to Gilead, which included the HBV (HB-400) and HIV (HB-500) programs, was a major component of the company's financial structure leading up to its decision to liquidate. This transaction involved specific, concrete payments that feed into the revenue recognition schedule.

Here are the key components related to the Gilead partnership that impact revenue streams:

• - The asset sale to Gilead included an immediate upfront payment of $3 million for the sale of the HBV/HIV programs.
• - The total potential payout from Gilead for these assets was structured to reach up to $422.5 million in milestones and royalties.
• - In July 2024, HOOKIPA Pharma Inc. received a success-based milestone payment of $5.0 million from Gilead related to the dosing of the first subject in the Phase 1b clinical trial of HB-500 for HIV-1.
• - The original 2018 collaboration agreement with Gilead provided an upfront payment of $10 million.
• - An amended 2022 agreement included a $15 million initiation fee and a $5 million equity investment from Gilead.

The sale of these vaccine rights to Gilead constituted substantially all of HOOKIPA Pharma Inc.'s assets, leading to the subsequent plan to wind down operations, as the company stated it has 'no product candidates that generate revenue.' This means the $9.35 million TTM revenue is largely the final recognition of these prior deals, not new, ongoing operational revenue.